Introduction:
Mycosis fungoides (MF) is a form of cutaneous T-cell lymphoma, a rare type of non-Hodgkin lymphoma that primarily affects the skin. While the classic presentation of MF is characterized by erythematous patches and plaques, a less common but equally important variant known as hypopigmented mycosis fungoides (HMF) exists. This subtype poses diagnostic challenges due to its atypical appearance, making it crucial for dermatologists and healthcare professionals to recognize and understand this distinct manifestation.
What Is Hypopigmented Mycosis Fungoide?
Mycosis fungoides (MF) is a common type of skin lymphoma with various clinical forms, including granulomatous, pustular, purpuric, hyperkeratotic, verrucous, bullous, invisible, and hypopigmented variants. The latter, hypopigmented MF (HMF), involves exclusively light-colored lesions. Initially associated with specific clinical forms, HMF is now considered a distinct subtype of MF. However, there are no established criteria for diagnosing typical HMF cases, and patients with other MF subtypes and hypochromic lesions may be misdiagnosed as having HMF.
What Is the Epidemiology of Hypopigmented Mycosis Fungoides?
Hypopigmented MF (HMF) differs from conventional MF by primarily affecting the pediatric population, with 17 to 59 percent of childhood MF cases being HMF. Studies show a median age of 17 at HMF diagnosis, contrasting with the typical onset for conventional MF in the fifth to sixth decades. HMF is predominantly observed in dark-skinned and Asian individuals, with Asians being more prone to HMF than classical MF. While classical MF is more prevalent in males, HMF shows no clear gender preference, though some studies suggest a female predominance. HMF is often misdiagnosed due to its resemblance to other conditions like vitiligo, pityriasis alba, leprosy, and postinflammatory hypopigmentation. The limited information on HMF contributes to underestimation and challenges incorrect diagnosis.
What Are the Clinical Features of Hypopigmented Mycosis Fungoides?
Distinctive clinical characteristics of hypopigmented mycosis fungoides (HMF) are given below.
-
HMF is identified by its unique hypopigmented-to-achromic lesions, resembling vitiligo.
-
These skin manifestations predominantly appear on the trunk and proximal parts of the extremities, including the buttocks, pelvic girdle, and lower limbs.
-
Variations may extend to distal extremities, such as the head and neck.
-
The size of these patches can vary, ranging from small droplet-sized lesions to larger plate-sized ones.
-
In some instances, patients present with a single lesion.
-
Itchiness is a common complaint, varying in intensity, yet local sensitivity remains intact.
-
Additional features include lesions with atrophy and telangiectasia, becoming more noticeable after exposure to sunlight.
How to Diagnose Hypopigmented Mycosis Fungoides?
Diagnosing hypopigmented mycosis fungoides typically involves a combination of clinical, histopathological, and immunohistochemical evaluations. The following are some steps involved in the diagnosis:
-
Clinical Examination: A dermatologist will thoroughly examine the patient, looking for hypopigmented or depigmented lesions on the skin. These lesions may be subtle and not easily visible, so a careful examination is crucial.
-
Skin Biopsy: A skin biopsy is often necessary to confirm the diagnosis. A small sample of the affected skin is taken and examined under a microscope to look for characteristic features of mycosis fungoides, such as atypical T-cell infiltration.
-
Histopathological Examination: The histopathological examination of the skin biopsy involves studying the cellular and structural characteristics of the skin tissue. Mycosis fungoides may have atypical lymphocytes infiltrating the epidermis and dermis.
-
Immunohistochemistry: Immunohistochemical staining of the biopsy sample can help identify the specific types of cells in the skin lesions. In mycosis fungoides, there is typically a predominance of T lymphocytes, and clear markers such as CD3, CD4, and CD8 may be used to characterize the cell population.
-
Molecular Testing: In some cases, molecular testing or gene expression profiling may be performed to aid in the diagnosis and classification of mycosis fungoides variants.
-
Follow-up and Monitoring: Follow-up evaluations are often necessary to monitor the progression of the disease. This may include periodic skin examinations, imaging studies, and other assessments to evaluate the extent of involvement.
What Are the Causes of Hypopigmented Mycosis Fungoides?
In hypopigmented mycosis fungoides (HMF), researchers used electron microscopy to examine skin cells. They found that abnormal melanin production and damage to melanocytes (cells that give color to the skin) may be causing the light patches on the skin. These changes are a response to cell damage and inflammation. Some studies suggest there might be a problem in transferring pigment-containing structures (melanosomes) from melanocytes to other skin cells, contributing to the light patches. Fortunately, this issue might be fixed with treatment.
Many CD8+ T cells in the affected skin suggest that these cells, part of the immune system, might be harming melanocytes and causing light patches. It is unclear if other CD8+ T cells without cancerous characteristics could have a similar effect, especially when more CD4+ T cells are present. Cancerous and non-cancerous immune cells may stop or damage melanocytes in the skin, leading to light patches.
In the early stages of mycosis fungoides (MF), the immune response involves a type called Th1, which helps fight against cancer. As the disease progresses, there is a shift to a different resistant type called Th2, which is linked to a worse outlook. In HMF, the light patches may result from a protective immune response involving CD8+ T cells, preventing the progression to a more harmful immune response associated with cancer.
Comparing how light patches form in vitiligo and HMF shows some similarities. Changes in specific proteins and molecules, like tumor necrosis factor-alpha (TNF-α) and a decrease in a protein called CD117 in melanocytes, are seen in both conditions. CD8+ T cells in the skin harm melanocytes, leading to problems or loss of these cells. These findings help us understand better how HMF develops and its similarities to other skin color disorders.
What Is the Treatment for Treatment Hypopigmented Mycosis Fungoides?
Phototherapy, especially a type called photochemotherapy, is the most commonly used method for treating hypopigmented mycosis fungoides (HMF). This method often leads to a quick and complete recovery, making it the first-choice treatment for HMF. Another type of light treatment, called narrow-band ultraviolet radiation, is also widely used, especially in children. While it may not work as well for people with darker skin, possibly because melanin provides some protection, it has shown effectiveness in Asian patients. Other effective treatments include topical nitrogen mustard or carmustine and total skin electron beam therapy. Since HMF often comes back even after treatment, using aggressive treatments is not recommended. Recurrences can happen months or even years after the skin condition has completely cleared up, so regular check-ups are essential to catch any return of symptoms early.
Conclusion
Hypopigmented mycosis fungoides (HMF) is a type of skin cancer that is more common in young people with darker skin. Even though the outlook for HMF is usually positive, it is important to treat it seriously as a malignant (cancerous) skin tumor. Regular check-ups are necessary, and it is crucial to avoid overly aggressive treatments because HMF often comes back after therapy.
